Hans van Houte, Chief Financial Officer at Nurix Therapeutics, Inc. (NRIX), sold 4,736 shares at $24.31 ($115K) on 2024-10-30, disclosed to the SEC on 2024-10-30.
Open-market sale of $115k NRIX by Chief Financial Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $24.31 | 2,368 | $58K | 50.0% |
| 2 | $24.31 | 2,368 | $58K | 50.0% |
| Total | $24.31 avg | 4,736 | $115K | 100% |
| Filing → |
| NRIX | SELL | 2026-05-05 | $233K | — | Filing → |
| NRIX | SELL | 2026-04-30 | $40K | — | Filing → |
| NRIX | SELL | 2026-01-30 | $122K | — | Filing → |